Please find enclosed herewith unaudited financial results for the quarter and nine months ended on 31st December 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has informed BSE that it has published newspaper advertisements regarding its standalone unaudited financial results for the quarter and nine months ended 31st December 2025, in compliance with SEBI LODR Regulation 47. The advertisements appeared in Financial Express (English) and Jansatta (Hindi) editions on 17th January 2026. The filing was signed by Managing Director Yogesh Agrawal (DIN: 01165288) and is purely a procedural disclosure confirming that results have been published in the newspapers as required. The actual detailed financial figures (revenue, profit/loss, EPS) are not shared in the body of this filing and would be available in the separately filed results document.
This is a routine regulatory compliance filing and does not signal any new business development. Investors should look for the separately filed Q3FY26 financial results document for actual numbers that could impact the stock price.